Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Anouk K. M. Claessens, Frans L. G. Erdkamp, Marta Lopez-Yurda, Jeanette M. Bouma, Jeany M. Rademaker-Lakhai, Aafke H. Honkoop, Hiltje de Graaf, Vivianne C. G. Tjan-Heijnen & Monique E. M. M. Bos. (2020) Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. Acta Oncologica 59:6, pages 713-722.
Read now
Read now
Cody P Coyne & Lakshmi Narayanan. (2016) Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549). Drug Design, Development and Therapy 10, pages 2575-2597.
Read now
Read now
Michael S Gordon. (2011) Antiangiogenic therapies: is VEGF-A inhibition alone enough?. Expert Review of Anticancer Therapy 11:3, pages 485-496.
Read now
Read now
David P Samuel, Patrick Y Wen & Mark W Kieran. (2009) Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opinion on Investigational Drugs 18:7, pages 973-983.
Read now
Read now
Articles from other publishers (42)
Marina Elena Cazzaniga, Serena Capici, Nicoletta Cordani, Viola Cogliati, Francesca Fulvia Pepe, Francesca Riva & Maria Grazia Cerrito. (2022) Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows. Journal of Clinical Medicine 11:16, pages 4710.
Crossref
Crossref
Marina Elena Cazzaniga, Nicoletta Cordani, Serena Capici, Viola Cogliati, Francesca Riva & Maria Grazia Cerrito. (2021) Metronomic Chemotherapy. Cancers 13:9, pages 2236.
Crossref
Crossref
Palma Fedele, Valeria Sanna, Alessandro Fancellu, Antonella Marino, Nicola Calvani & Saverio Cinieri. (2021) De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?. Critical Reviews in Oncology/Hematology 157, pages 103148.
Crossref
Crossref
O. Graciela Scharovsky, María José Rico, Leandro E. Mainetti, Herman A. Perroud & Viviana R. Rozados. (2020) Achievements and challenges in the use of metronomics for the treatment of breast cancer. Biochemical Pharmacology 175, pages 113909.
Crossref
Crossref
Cem Simsek, Ece Esin & Suayib Yalcin. (2019) Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience. Journal of Oncology 2019, pages 1-31.
Crossref
Crossref
Cody P. Coyne & Lakshmi Narayanan. (2018) Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]. Journal of Pharmaceutical Investigation 49:1, pages 173-193.
Crossref
Crossref
Malgorzata Banys-Paluchowski, Tanja Fehm & Volkmar Müller. 2019. Tumor Angiogenesis. Tumor Angiogenesis
515
527
.
Marina Elena Cazzaniga, Maria Rita Dionisio & Francesca Riva. (2017) Metronomic chemotherapy for advanced breast cancer patients. Cancer Letters 400, pages 252-258.
Crossref
Crossref
Adriana Romiti, Rosa Falcone, Michela Roberto & Paolo Marchetti. (2016) Current achievements and future perspectives of metronomic chemotherapy. Investigational New Drugs 35:3, pages 359-374.
Crossref
Crossref
Yangyang Liu, Feifei Gu, Jinyan Liang, Xiaomeng Dai, Chao Wan, Xiaohua Hong, Kai Zhang & Li Liu. (2017) The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis. PLOS ONE 12:3, pages e0173693.
Crossref
Crossref
Cody P. Coyne & Lakshmi Narayanan. (2017)
Gemcitabine-(
5′-phosphoramidate
)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)
. Chemical Biology & Drug Design 89:3, pages 379-399.
Crossref
Crossref
Malgorzata Banys-Paluchowski, Tanja Fehm & Volkmar M?ller. 2017. Tumor Angiogenesis. Tumor Angiogenesis
1
13
.
Fatima Cardoso, Marco Colleoni, Angelo Di Leo, Giulio Francia, Alessandra Gennari, Joseph Gligorov & Antonio Llombart. (2016) Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. Cancer Treatment Communications 6, pages S1-S10.
Crossref
Crossref
Elisabetta Munzone & Marco Colleoni. (2015) Clinical overview of metronomic chemotherapy in breast cancer. Nature Reviews Clinical Oncology 12:11, pages 631-644.
Crossref
Crossref
Kwan-Hwa Chi, Hui-Ling Ko, Kai-Lin Yang, Cheng-Yen Lee, Mau-Shin Chi & Shang-Jyh Kao. (2015) Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort. Oncotarget 6:18, pages 16735-16745.
Crossref
Crossref
Cheryl A. London, Heather L. Gardner, Tamra Mathie, Nicole Stingle, Roberta Portela, Michael L. Pennell, Craig A. Clifford, Mona P. Rosenberg, David M. Vail, Laurel E. Williams, Kim L. Cronin, Heather Wilson-Robles, Antonella Borgatti, Carolyn J. Henry, Dennis B. Bailey, Jennifer Locke, Nicole C. Northrup, Martin Crawford-Jakubiak, Virginia L. Gill, Mary K. Klein, David M. Ruslander, Doug H. Thamm, Brenda Phillips & Gerald Post. (2015) Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLOS ONE 10:4, pages e0124889.
Crossref
Crossref
C. P. Coyne, Toni Jones & Ryan Bear. (2015) Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine. Journal of Cancer Therapy 06:01, pages 62-89.
Crossref
Crossref
Emilia Montagna, Giuseppe Cancello, Silvia Dellapasqua, Elisabetta Munzone & Marco Colleoni. (2014) Metronomic therapy and breast cancer: A systematic review. Cancer Treatment Reviews 40:8, pages 942-950.
Crossref
Crossref
Iben K?mler, Ole Grummedal Christiansen & Dorte Lisbet Nielsen. (2014) A systematic review of bevacizumab efficacy in breast cancer. Cancer Treatment Reviews 40:8, pages 960-973.
Crossref
Crossref
Elisabetta Munzone, Francesco Bertolini & Marco Colleoni. 2014. Metronomic Chemotherapy. Metronomic Chemotherapy
93
110
.
Keemo Delos Santos, Kelly Lien, Soley Georgsdottir, Lavarnan Sivanathan & Urban Emmenegger. 2014. Metronomic Chemotherapy. Metronomic Chemotherapy
263
279
.
Adriana Romiti, M. Christina Cox, Ida Sarcina, Roberta Di Rocco, Chiara D?Antonio, Viola Barucca & Paolo Marchetti. (2013) Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemotherapy and Pharmacology 72:1, pages 13-33.
Crossref
Crossref
L. Manso, N. Valdiviezo, J. Sepúlveda, E. Ciruelos, C. Mendiola, I. Ghanem, E. Vega, R. Manneh, M. Dorta & H. Cortés-Funes. (2012) Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. Clinical and Translational Oncology 15:6, pages 467-471.
Crossref
Crossref
. 2013. Withrow and MacEwen's Small Animal Clinical Oncology. Withrow and MacEwen's Small Animal Clinical Oncology
215
244
.
Erica L. Mayer, Steven J. Isakoff, Giannoula Klement, Sean R. Downing, Wendy Y. Chen, Keri Hannagan, Rebecca Gelman, Eric P. Winer & Harold J. Burstein. (2012) Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Research and Treatment 136:1, pages 169-178.
Crossref
Crossref
C. London, T. Mathie, N. Stingle, C. Clifford, S. Haney, M. K. Klein, L. Beaver, K. Vickery, D. M. Vail, B. Hershey, S. Ettinger, A. Vaughan, F. Alvarez, L. Hillman, M. Kiselow, D. Thamm, M. L. Higginbotham, M. Gauthier, E. Krick, B. Phillips, T. LaDue, P. Jones, J. Bryan, V. Gill, A. Novasad, L. Fulton, J. Carreras, C. McNeill, C. Henry & S. Gillings. (2012)
Preliminary evidence for biologic activity of toceranib phosphate (Palladia
®
) in solid tumours
. Veterinary and Comparative Oncology 10:3, pages 194-205.
Crossref
Crossref
Ana Elisa Lohmann & Stephen Chia. (2012) Patients With Metastatic Breast Cancer Using Bevacizumab as a Treatment: Is There Still a Role for it?. Current Treatment Options in Oncology 13:2, pages 249-262.
Crossref
Crossref
Giacomo Allegrini, Teresa Di Desidero, Maria Teresa Barletta, Anna Fioravanti, Paola Orlandi, Bastianina Canu, Silvio Chericoni, Fotios Loupakis, Antonello Di Paolo, Gianluca Masi, Andrea Fontana, Sara Lucchesi, Giada Arrighi, Mario Giusiani, Andrea Ciarlo, Giovanni Brandi, Romano Danesi, Robert S. Kerbel, Alfredo Falcone & Guido Bocci. (2012) Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 15:2, pages 275-286.
Crossref
Crossref
Christina E Stevenson, Masayuki Nagahashi, Subramaniam Ramachandran, Akimitsu Yamada, Harry D BearKazuaki Takabe. (2012) Bevacizumab and breast cancer: what does the future hold?. Future Oncology 8:4, pages 403-414.
Crossref
Crossref
Cody P. CoyneToni JonesRyan Bear. (2012)
Synthesis of a Covalent Epirubicin-(C
3
-
amide
)-Anti-HER2/
neu
Immunochemotherapeutic Utilizing a UV-Photoactivated Anthracycline Intermediate
. Cancer Biotherapy and Radiopharmaceuticals 27:1, pages 41-55.
Crossref
Crossref
Cody P. Coyne, Toni Jones & Ryan Bear. (2012) Synthesis of Gemcitabine-(C<sub>4</sub>-<i>amide</i>)-[anti-HER2/<i>neu</i>] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3. Journal of Cancer Therapy 03:05, pages 689-711.
Crossref
Crossref
Peter Bojko, Gudrun Schimmel, Daniel Bosse & Wolfgang Abenhardt. (2012) Metronomic Oral Cyclophosphamide in Patients with Advanced Solid Tumors. Onkologie 35:1-2, pages 35-38.
Crossref
Crossref
Una Adamcic, Clorinda Castagna, Kanwal Minhas, Siranoush Shahrzad & Brenda L. Coomber. (2012) Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human Melanoma. Journal of Oncology 2012, pages 1-9.
Crossref
Crossref
Aris Polyzos, Kostas Kalbakis, Nikolaos Kentepozidis, Stylianos Giassas, Antonia Kalykaki, Nikolaos Vardakis, Vasiliki Bozionelou, Emmanouel Saloustros, Emmanouel Kontopodis, Vassilis Georgoulias & Dimitris Mavroudis. (2010) Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab. Cancer Chemotherapy and Pharmacology 68:1, pages 217-223.
Crossref
Crossref
Margarida Damasceno. (2011) Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer. Current Opinion in Oncology 23, pages S3-S9.
Crossref
Crossref
Cody P. Coyne, Toni Jones, Andrzej Sygula, John Bailey & Lesya Pinchuk. (2011) Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium. Journal of Cancer Therapy 02:01, pages 22-39.
Crossref
Crossref
C.P. Coyne, Toni Jones & Todd Pharr. (2011) Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma. Bioorganic & Medicinal Chemistry 19:1, pages 67-76.
Crossref
Crossref
L.Y. DirixP.A. Van Dam, A.M. Prove & P.B. Vermeulen. (2010) Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?. Therapeutic Advances in Medical Oncology 2:5, pages 331-342.
Crossref
Crossref
Eddy Pasquier, Maria Kavallaris & Nicolas André. (2010) Metronomic chemotherapy: new rationale for new directions. Nature Reviews Clinical Oncology 7:8, pages 455-465.
Crossref
Crossref
Angelos K. Koutras, George Fountzilas, Thomas Makatsoris, Stavros Peroukides & Haralabos P. Kalofonos. (2010) Bevacizumab in the treatment of breast cancer. Cancer Treatment Reviews 36:1, pages 75-82.
Crossref
Crossref
Douglas M. Noonan, Giuseppina Pennesi & Adriana Albini. 2010. The Tumor Microenvironment. The Tumor Microenvironment
213
228
.
D A Reardon, A Desjardins, J J Vredenburgh, S Gururangan, J H Sampson, S Sathornsumetee, R E McLendon, J E Herndon, J E Marcello, J Norfleet, A H Friedman, D D Bigner & H S Friedman. (2009) Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. British Journal of Cancer 101:12, pages 1986-1994.
Crossref
Crossref